Provided by Tiger Trade Technology Pte. Ltd.

Arcturus Therapeutics Ltd.

6.63
-0.0500-0.75%
Post-market: 6.630.00000.00%16:00 EDT
Volume:651.03K
Turnover:4.31M
Market Cap:188.38M
PE:-2.76
High:6.80
Open:6.79
Low:6.50
Close:6.68
52wk High:24.17
52wk Low:5.85
Shares:28.41M
Float Shares:26.28M
Volume Ratio:1.33
T/O Rate:2.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4021
EPS(LYR):-2.4021
ROE:-28.92%
ROA:-15.49%
PB:0.88
PE(LYR):-2.76

Loading ...

May 10, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
May 09, 2023

Major Issues Report

8-K - Current report
May 09, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 28, 2023

Major Issues Report

8-K - Current report
Apr 21, 2023

Major Issues Report

8-K - Current report
Apr 17, 2023

Proposed Sale Of Securities

144 - Report of proposed sale of securities
Apr 11, 2023

Major Issues Report

8-K - Current report
Mar 29, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 28, 2023

Major Issues Report

8-K - Current report
Mar 17, 2023

Major Issues Report

8-K - Current report
Feb 10, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 03, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 01, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Dec 30, 2022

Correspondence

CORRESP [Cover] - Correspondence
Dec 13, 2022

Major Issues Report

8-K - Current report
Dec 13, 2022

Major Issues Report

8-K - Current report
Nov 09, 2022

Major Issues Report

8-K - Current report
Nov 09, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]